Want to see JP:2796 full AI Analyst Report?
Top Page
Pharmarise Holdings Corp.
(2796)
Select Model
Select Model
Rating:59Neutral
Price Target:
¥532.00
▲(2.11% Upside)
Action:Reiterated
Date:06/26/26
The score is driven primarily by solid revenue growth and notably stronger recent operating and free cash flow, plus meaningful debt reduction in 2026. These positives are tempered by highly inconsistent profitability and thin net margins, while technical signals appear mixed and valuation is harder to assess due to a negative P/E despite a moderate dividend yield.
Positive Factors
Sustained Revenue Growth
Revenue expansion from ~52.3B in 2021 to ~69.5B in 2026 shows durable top-line momentum. Persistent sales growth supports scale economics, market positioning and reinvestment capacity, underpinning longer-term recovery in operating margins and funding for R&D or market expansion.
Negative Factors
Inconsistent Profitability
The company had losses in 2024–2025 and only a very small profit in 2026 (~0.11B on ~69.5B revenue), reflecting highly inconsistent profitability. Persistent thin net margins signal structural sensitivity to cost, pricing or mix, limiting predictability of durable earnings and reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue expansion from ~52.3B in 2021 to ~69.5B in 2026 shows durable top-line momentum. Persistent sales growth supports scale economics, market positioning and reinvestment capacity, underpinning longer-term recovery in operating margins and funding for R&D or market expansion.
Read all positive factors
Pharmarise Holdings Corp. (2796) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.93B
Dividend Yield2.77%
Average Volume (3M)3.38K
Price to Earnings (P/E)50.3
Beta (1Y)0.12
Revenue Growth9.45%
EPS GrowthN/A
CountryJP
Employees2,031
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)10.04
Shares Outstanding12,060,381
10 Day Avg. Volume3,660
30 Day Avg. Volume3,376
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.85
Price to Sales (P/S)0.08
P/FCF Ratio2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmarise Holdings Corp. Business Overview & Revenue Model
Company Description
Pharmarise Holdings Corporation predominantly oversees a chain of pharmacies that dispense prescription medications throughout Japan. These establishments fulfill prescriptions provided by medical facilities, offering vital pharmaceutical services...
How the Company Makes Money
null...
Pharmarise Holdings Corp. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
52
Neutral
Cash Flow
70
Positive
| Breakdown | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 69.51B | 63.51B | 54.47B | 52.03B | 51.61B |
| Gross Profit | 8.64B | 8.20B | 7.89B | 7.50B | 7.42B |
| EBITDA | 2.58B | 1.68B | 1.38B | 2.33B | 2.69B |
| Net Income | 113.00M | -368.00M | -351.00M | 333.00M | 448.00M |
Balance Sheet | |||||
| Total Assets | 32.68B | 31.99B | 29.54B | 23.46B | 23.78B |
| Cash, Cash Equivalents and Short-Term Investments | 6.01B | 4.91B | 7.15B | 4.74B | 3.99B |
| Total Debt | 15.15B | 14.28B | 12.75B | 9.14B | 9.91B |
| Total Liabilities | 25.82B | 25.07B | 22.10B | 16.47B | 17.08B |
| Stockholders Equity | 6.84B | 6.87B | 7.36B | 6.88B | 6.61B |
Cash Flow | |||||
| Free Cash Flow | 2.58B | 674.00M | 2.24B | 2.14B | 334.00M |
| Operating Cash Flow | 3.28B | 1.31B | 2.71B | 2.52B | 713.00M |
| Investing Cash Flow | -1.98B | -4.46B | -3.12B | -703.00M | -292.00M |
| Financing Cash Flow | -181.00M | 939.00M | 2.77B | -1.07B | -1.03B |
Pharmarise Holdings Corp. Technical Analysis
Positive
521.00
Price Trends
492.40
Positive
500.39
Positive
503.46
Positive
Market Momentum
3.35
Negative
66.60
Neutral
91.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2796, the sentiment is Positive. The current price of 521 is above the 20-day moving average (MA) of 499.35, above the 50-day MA of 492.40, and above the 200-day MA of 503.46, indicating a bullish trend. The MACD of 3.35 indicates Negative momentum. The RSI at 66.60 is Neutral, neither overbought nor oversold. The STOCH value of 91.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2796.
Pharmarise Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥43.69B | 13.12 | ― | 2.55% | 3.38% | 32.41% | |
66 Neutral | ¥51.20B | -76.26 | ― | ― | ― | ― | |
59 Neutral | ¥5.93B | 50.30 | ― | 2.77% | 9.45% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ¥15.15B | 16.90 | ― | 2.39% | 8.19% | -25.81% | |
52 Neutral | ¥14.27B | 18.85 | ― | 2.90% | 2.87% | -73.55% | |
38 Underperform | ¥5.49B | -3.54 | ― | ― | ― | 33.26% |
* General Sector Average
JP:2796
Pharmarise Holdings Corp.
505.00
15.19
3.10%
JP:3417
Ohki Health Care Holdings, Inc.
1,035.00
-333.90
-24.39%
JP:4350
Medical System Network Co., Ltd.
502.00
23.36
4.88%
JP:4931
Shinnihonseiyaku Co., Ltd.
2,041.00
-287.74
-12.36%
JP:190A
Chordia Therapeutics Inc.
71.00
-78.00
-52.35%
JP:219A
Heartseed, Inc.
2,236.00
-1,519.00
-40.45%
Pharmarise Holdings Corp. Corporate Events
Pharmarise Returns to Profit as Sales Rise, Warns of Profit Slowdown in 2027
Jun 25, 2026
Pharmarise Holdings reported consolidated net sales of ¥69.5 billion for the fiscal year ended May 31, 2026, up 9.5% year on year, with operating profit surging to ¥979 million and a return to profitability at the parent level after a lo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.